person · Reporting owner
Arjona Ferreira Juan Camilo
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Head of R&D & CMO | August 11, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,432.477 |
Ending reported balance
After 2026-08-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-11 · Exercise / conversion · Acquired 11,519 · Balance 41,566.477 Row 2 · 2026-08-11 · Tax withholding · Disposed 4,134 · Balance 37,432.477 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-11 · Exercise / conversion · Acquired 11,519 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.
F2: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-10 · Disposition to issuer · Disposed 86,602 · Balance 160,082 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"). Row 2 · 2023-03-10 · Disposition to issuer · Disposed 160,082 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2027-08-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 155,300 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2028-04-15 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 63,717 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2029-04-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Disposition to issuer · Disposed 65,863 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F6: One-fourth of the options vested on April 5, 2020, and one-sixteenth of the options vest each quarter thereafter. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2030-04-02 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Disposition to issuer · Disposed 134,464 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F7: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.88 · Expires 2031-04-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-10 · Disposition to issuer · Disposed 79,472 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F8: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-10 · Disposition to issuer · Disposed 103,703 · Balance 0 F9: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration").
F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
F6: One-fourth of the options vested on April 5, 2020, and one-sixteenth of the options vest each quarter thereafter.
F7: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter.
F8: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter.
F9: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2020 Filed Sep 17, 2020 20:18 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 7,000 | $7.78 | $54,460.00 |
DisclosureSEC source: 0001209191-20-050883 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,307 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-049162 · doc4.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,267 Underlying: Common Shares · 11,307 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 11,307 | $20.01 | $226,196.54 |
DisclosureSEC source: 0001209191-20-049162 · doc4.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,026 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $20.00 to $20.03. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 11,307 | $7.78 | $87,968.46 |
DisclosureSEC source: 0001209191-20-049162 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,791 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-048799 · doc4.xml · derivative · entry 5 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,574 Underlying: Common Shares · 1,791 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 267 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-048799 · doc4.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,863 Underlying: Common Shares · 267 shares Expires 2029-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 2,058 | $20.01 | $41,180.58 |
DisclosureSEC source: 0001209191-20-048799 · doc4.xml · nonDerivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,026 F3 · shares: Shares sold pursuant to a 10b5-1 trading plan. F4 · price: The shares were sold at prices ranging from $20.00 to $20.05. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 2,058 | $7.78 | $16,011.24 |
DisclosureSEC source: 0001209191-20-048799 · doc4.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 7,089 | $18.80 | $133,273.20 |
DisclosureSEC source: 0001209191-20-048799 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,026 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $18.80 to $18.905. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 635 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-047961 · doc4.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,365 Underlying: Common Shares · 635 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 130,000 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 635 | $20.00 | $12,700.00 |
DisclosureSEC source: 0001209191-20-047961 · doc4.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,115 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 21:02 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 635 | $7.78 | $4,940.30 |
DisclosureSEC source: 0001209191-20-047961 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:23 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-039080 · doc4.xml · derivative · entry 5 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,550 Underlying: Common Stock · 6,500 shares Expires 2028-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 27,204 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:23 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,946 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-039080 · doc4.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 10,946 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 130,000 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:23 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 17,446 | $20.00 | $348,920.00 |
DisclosureSEC source: 0001209191-20-039080 · doc4.xml · nonDerivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,115 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:23 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Stock | 6,500 | $7.78 | $50,570.00 |
DisclosureSEC source: 0001209191-20-039080 · doc4.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:23 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Stock | 10,946 | $7.78 | $85,159.88 |
DisclosureSEC source: 0001209191-20-039080 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:16 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,054 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-038726 · doc4.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,946 Underlying: Common Stock · 4,054 shares Expires 2027-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 130,000 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:16 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 4,054 | $20.00 | $81,080.00 |
DisclosureSEC source: 0001209191-20-038726 · doc4.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,115 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:16 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Stock | 4,054 | $7.78 | $31,540.12 |
DisclosureSEC source: 0001209191-20-038726 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:08 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 134,464 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0001209191-20-023793 · doc4.xml · derivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,464 Underlying: Common Shares · 134,464 shares Expires 2030-04-02 F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:08 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 87,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023793 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,115 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 66,130 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · derivative · entry 7 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,130 Underlying: Common Shares · 66,130 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 66,130 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · derivative · entry 6 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 66,130 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 87,050 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · derivative · entry 5 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,050 Underlying: Common Shares · 87,050 shares Expires 2028-04-15 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 87,050 | $0.00 Strike: $21.87 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 87,050 shares Expires 2028-04-15 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Shares · 260,000 shares Expires 2027-08-14 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · derivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 260,000 shares Expires 2027-08-14 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:53 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 47,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047541 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,310 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:16 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 66,130 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-024135 · doc4.xml · derivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,130 Underlying: Common Stock · 66,130 shares Expires 2029-05-04 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:25 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 260 | $21.15 | $5,499.00 |
DisclosureSEC source: 0001209191-19-011541 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,740 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 22:39 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 87,050 | $0.00 Strike: $21.87 | $0.00 |
DisclosureSEC source: 0001209191-18-025451 · doc4.xml · derivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,050 Underlying: Common Shares · 87,050 shares Expires 2028-04-15 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 16, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter measured from April 16, 2019, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:19 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001209191-17-049519 · doc4.xml · derivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Shares · 260,000 shares Expires 2027-08-14 F3 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on August 15, 2018, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter measured from August 15, 2018, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:19 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049519 · doc4.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · security: Represents common shares underlying a restricted stock unit award. F2 · shares: 1/4 of the common shares underlying this restricted stock unit award vest on August 16, 2018, and 1/16 of the common shares underlying this restricted stock unit award vest on each November 16, February 16, July 1 and August 16 thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.